[NEW YORK] US stocks rose for a fourth straight session on Monday, with both the Dow and S&P 500 ending at records as large-cap technology shares gained and offset continued weakness in energy names.
Major indexes opened with slight gains but strengthened throughout the session, ending near their highs of the day. Despite that, trading was quiet with many market participants out ahead of the upcoming Christmas holiday.
About 6.41 billion shares traded on all US platforms, according to BATS exchange data, compared with the month-to-date average of 7.86 billion.
Tech was the strongest sector of the day, with the S&P information technology sector up 1.1 per cent. Intel Corp rose 2.3 per cent to US$37.21, providing the biggest boost to the Dow, while IBM rose 1.8 per cent to US$161.44 and Cisco Systems rose 1.6 per cent to US$28.22. Priceline Group rose 3.6 per cent to US$1,149.38. "I wouldn't put a lot of weight on this week's trading, given year-end maneuvers and how slow it is," said Rex Macey, chief allocation officer at Wilmington Trust Investment Advisors in Atlanta, Georgia. "While I'm comfortable with the level of the broader market, I don't think there are obvious bargains. Some may say oil stocks are bargains now, but it's too soon to say." Crude oil sank 3.2 per cent after Saudi Arabia's powerful oil minister said Opec would not cut production at any price. The S&P energy index fell 1 per cent as one of the day's weakest sectors; Chesapeake Energy fell 7.3 per cent to US$18.42 while Southwestern Energy was off 5.5 per cent at US$29.31.
Crude oil is coming off four straight weeks of declines, and has fallen in 11 of the past 12 completed weeks.
The Dow Jones industrial average rose 154.64 points, or 0.87 per cent, to 17,959.44, the S&P 500 gained 7.89 points, or 0.38 per cent, to 2,078.54 and the Nasdaq Composite added 16.04 points, or 0.34 per cent, to 4,781.42.
Both the Dow and S&P ended at closing records, with the benchmark S&P building on a 3.4 per cent rise last week. That advance came after the US Federal Reserve said it would take a "patient" approach toward raising interest rates and oil prices appeared to stabilise.
Gilead slumped 14 per cent to US$92.90 as the biggest drag on both the S&P and Nasdaq 100. Express Scripts , the nation's largest pharmacy benefit manager, said it would no longer cover Gilead's treatments after it lined up a cheaper price from AbbVie Inc for its newly approved hepatitis C treatment.
Achillion Pharmaceuticals Inc said it would test a combination of two of its experimental hepatitis C drugs which showed promise in separate studies. Shares surged 10 per cent to US$15.61.
Advancing issues outnumbered declining ones on the NYSE by 1,806 to 1,291, for a 1.40-to-1 ratio on the upside; on the Nasdaq, 1,682 issues rose and 1,072 fell for a 1.57-to-1 ratio favoring advancers.
The benchmark S&P 500 index was posting 73 new 52-week highs and 5 new lows; the Nasdaq Composite was recording 144 new highs and 36 new lows.